In our study, we established a standardized protocol to measure free-circulating soluble Aβ42/40/total-tau, NDEVs, and their content in Aβ42/40/tau by Simoa in human plasma samples, with the goal of assessing their potential as AD biomarkers. Here, MAPT is linked to Alzheimer disease.